NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that results from its PARADIGM Phase 2b clinical trial evaluating the investigational therapy PrimeC in amyotrophic lateral sclerosis have been published in JAMA Neurology, a development that strengthens the scientific foundation for advancing the program into Phase 3. The peer-reviewed publication integrates clinical outcomes, biomarker analysis, and long-term follow-up data demonstrating slower functional decline and reduced risk of ALS-related complications among patients treated with PrimeC. NeuroSense Therapeutics indicated that the findings reinforce the therapy’s potential as a disease-modifying treatment rather than merely a symptomatic intervention. The publication also signals growing scientific validation of the company’s multi-pathway therapeutic approach to one of the most challenging neurodegenerative diseases.

The publication represents a significant credibility milestone for NeuroSense Therapeutics because peer-reviewed journals often serve as a gatekeeper for how clinical data is interpreted by regulators, physicians, and institutional investors. By placing the PARADIGM results in one of neurology’s most influential journals, the company effectively moves the discussion of PrimeC beyond conference presentations and press releases into the realm of formal scientific validation.

Why does the JAMA Neurology publication of the PARADIGM trial strengthen NeuroSense Therapeutics’ clinical development strategy for PrimeC in ALS?

Amyotrophic lateral sclerosis remains one of the most devastating neurodegenerative diseases, with limited treatment options and a relentless progression that typically leads to respiratory failure within several years of diagnosis. Existing therapies have historically delivered modest survival extensions rather than transformative disease-modifying effects, leaving a substantial therapeutic gap that continues to attract both academic research and biotech investment.

Within this context, the PARADIGM Phase 2b trial represents an attempt by NeuroSense Therapeutics to approach ALS treatment through simultaneous modulation of multiple disease pathways. The randomized, double-blind, placebo-controlled study evaluated PrimeC during a six-month blinded treatment phase followed by a 12-month open-label extension period.

The trial enrolled 68 patients with definite or probable ALS across several international clinical centers. Participants were randomized in a 2:1 ratio to receive either PrimeC or placebo during the blinded phase. After six months, all participants entered an open-label extension in which they received the investigational therapy while maintaining blinding regarding their original assignment.

Although the study was not statistically powered to demonstrate definitive efficacy, the data showed consistent signals of potential clinical benefit across multiple endpoints. According to the published findings, patients who began PrimeC treatment at the outset maintained a 7.92-point advantage on the ALS Functional Rating Scale Revised after 18 months. This difference corresponded to more than a 36 percent slowing in disease progression compared with those who initially received placebo.

Such functional metrics are particularly important in ALS research because the ALSFRS-R scale directly reflects patient mobility, speech, swallowing ability, and respiratory function. Even moderate changes on the scale can translate into meaningful improvements in quality of life and independence.

What do the clinical outcomes from the PARADIGM trial suggest about PrimeC’s potential disease-modifying effects in ALS?

One of the most notable aspects of the PARADIGM results lies in the convergence of clinical outcomes and biomarker signals. Clinical studies in neurodegenerative diseases often struggle to demonstrate alignment between patient outcomes and underlying biological markers. When such alignment occurs, it tends to strengthen confidence that a therapy is affecting the disease itself rather than merely masking symptoms.

The PARADIGM data suggested that continuous treatment with PrimeC slowed functional decline and improved long-term outcomes. The largest improvements were observed in bulbar function, an ALS domain affecting speech and swallowing. Bulbar deterioration is often one of the most debilitating aspects of the disease, and improvements in this area can meaningfully affect patient autonomy and nutritional health.

The study also reported a reduction in ALS-related complications. Early initiation of PrimeC was associated with a 64 percent relative reduction in the risk of major disease complications including respiratory failure, hospitalization, or death. While such findings require confirmation in larger studies, they hint at the possibility that early intervention may significantly alter disease trajectories.

From a safety perspective, PrimeC demonstrated a tolerability profile comparable to placebo across the 18-month observation period. Most treatment-related adverse events were mild to moderate and transient. Safety remains a critical factor in ALS therapy development because patients typically require long-term treatment.

How do biomarker findings in the PARADIGM trial reinforce the biological rationale for PrimeC’s multi-pathway ALS approach?

Beyond clinical outcomes, the PARADIGM trial produced biomarker evidence that supports PrimeC’s proposed mechanism of action. ALS research has increasingly focused on understanding how multiple biological pathways contribute to disease progression, including neuroinflammation, oxidative stress, and dysregulated iron metabolism.

PrimeC is designed as a fixed-dose oral combination therapy that targets several of these mechanisms simultaneously. The formulation combines celecoxib and ciprofloxacin in a synchronized extended-release composition aimed at modulating inflammatory pathways, correcting iron dysregulation, and influencing microRNA-mediated regulatory networks associated with neurodegeneration.

The PARADIGM study identified favorable changes in markers related to iron metabolism, including preservation of transferrin levels and stabilization of ferritin. Dysregulated iron metabolism has been increasingly recognized as a potential contributor to neuronal damage in ALS, making these findings particularly relevant.

The trial also demonstrated statistically significant reductions in several microRNAs associated with ALS progression and severity. Among the downregulated biomarkers were miR-199a-3p, miR-199a-5p, miR-181a-5p, and miR-181b-5p, all of which have been linked to disease activity in prior research.

The alignment between biomarker modulation and clinical outcomes suggests that PrimeC may be engaging biological pathways directly implicated in disease progression. Such convergence is often viewed by regulators as supportive evidence when evaluating whether a therapy could have disease-modifying potential.

What does the PARADIGM publication signal about NeuroSense Therapeutics’ path toward a confirmatory Phase 3 ALS trial?

For NeuroSense Therapeutics, the JAMA Neurology publication arrives at a strategically important moment. The company has already indicated that the PARADIGM findings informed the design of a planned Phase 3 trial evaluating PrimeC in ALS.

Phase 3 trials represent the final and most demanding stage of clinical development. These studies must demonstrate robust efficacy and safety across larger patient populations while satisfying regulatory expectations from agencies such as the United States Food and Drug Administration and the European Medicines Agency.

The publication strengthens the scientific case for moving forward by demonstrating that multiple clinical endpoints and biological signals point in the same direction. Consistency across datasets often becomes a deciding factor when regulators evaluate whether earlier studies justify larger confirmatory trials.

The involvement of internationally recognized ALS research institutions in the PARADIGM study also adds credibility. Investigators from major centers including Mass General Brigham, Barrow Neurological Institute, University of Torino, and Tel-Aviv Sourasky Medical Centre contributed to the research. Multinational investigator participation often signals that the clinical development program is attracting broad academic engagement.

How might the PARADIGM data influence investor sentiment toward NeuroSense Therapeutics and the broader ALS drug development landscape?

For investors tracking neurodegenerative disease pipelines, ALS programs often represent high-risk, high-impact opportunities. Historically, many experimental therapies have failed in late-stage trials, creating a cautious investment environment for ALS-focused biotechnology companies.

The PARADIGM publication does not eliminate the scientific uncertainty inherent in ALS drug development, but it does strengthen the narrative that PrimeC may have measurable biological activity. Investors often look for three signals when evaluating early-stage therapies: clinical improvement, biomarker alignment, and a credible regulatory path. The PARADIGM results appear to touch all three.

At the same time, market participants are likely to remain cautious until larger Phase 3 data become available. Neurodegenerative diseases frequently produce encouraging Phase 2 signals that do not always translate into confirmatory outcomes in larger trials.

However, the fact that the study demonstrated benefits across several endpoints may provide a stronger foundation than single-endpoint improvements seen in some earlier ALS studies. If Phase 3 results ultimately replicate these findings, PrimeC could become part of a new generation of therapies aiming to alter disease progression rather than simply slowing symptoms.

Key takeaways on what the PARADIGM Phase 2b publication means for NeuroSense Therapeutics and the ALS treatment landscape

• The JAMA Neurology publication significantly strengthens the scientific credibility of the PARADIGM Phase 2b trial results for PrimeC.

• Consistent clinical outcomes and biomarker signals suggest PrimeC may influence underlying ALS disease mechanisms.

• Patients treated with PrimeC showed slower functional decline and improved long-term ALSFRS-R scores.

• Early treatment was associated with a substantial reduction in ALS-related complications such as respiratory failure and hospitalization.

• Biomarker data indicate modulation of iron metabolism and ALS-associated microRNA pathways.

• The results support NeuroSense Therapeutics’ strategy to advance PrimeC into a confirmatory Phase 3 clinical trial.

• Multinational investigator participation enhances the credibility of the clinical research program.

• The publication may improve investor confidence but does not remove the high development risk typical in ALS drug research.

• If confirmed in Phase 3, PrimeC could represent a potential disease-modifying therapy rather than a symptomatic treatment.

• The broader ALS drug development field continues to shift toward multi-pathway therapeutic strategies.